14th Jul 2025 18:27
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
----------
Ondine Biomedical Inc - Vancouver, Canada-based life sciences company - Reports the "growing use" of Steriwave nasal decolonisation in hospitals prior to major surgeries, including cardiac, orthopaedic, neurosurgical, ENT, spinal, and cosmetic procedures. Steriwave is a non-invasive nasal treatment that destroys harmful bacteria, viruses and fungi, and is used actively in more than half of Canada's ten largest hospitals. "It's encouraging to see Steriwave gaining recognition across such a wide range of surgical specialties. In contrast to mupirocin - the current standard for nasal decolonisation despite its limited bacterial spectrum and rising resistance - Steriwave offers a fast-acting, resistance-free alternative...In some hospitals, mupirocin resistance exceeds 70%, underscoring the urgent need for more versatile and reliable infection prevention tools like Steriwave," says Ondine Chief Executive Officer Carolyn Cross. Steriwave is currently undergoing a phase 3 clinical trial in the US, which aims to secure Food & Drug Administration marketing approval.
----------
Fragrant Prosperity Holdings Ltd - British Virgin Islands-based special purpose acquisition company - Says its recent fundraise and recapitalisation has now completed, and that the firm is now focused on the identification of a "suitable target" to acquire. "It is an exciting time to be searching for potential targets in the fintech space," says the company. "With a global reach, scalable tech is shaping the future of numerous industries including financial services. The kind of businesses that would be suitable for FPP are ones that are robust enough to not face significant challenges as a result of the uncertain global backdrop. We are optimistic with our approach and the [investment advisory boards] and board will carefully consider the best options for all shareholders and will make any relevant announcements in due course as the search progresses".
----------
Vaultz Capital PLC - operating company building a scalable, revenue-generating business through participation in bitcoin network infrastructure - Raises GBP1.0 million through a placing of 6.1 million new shares at 16.5 pence each on Friday, which will be used to "continue executing the company's operational business and bitcoin treasury strategy. Vaultz Capital intends to build a strategic position in bitcoin over a multi-year horizon, with the intention of becoming "a leading corporate holder" in the cryptocurrency, it says.
----------
Helix Exploration PLC - London-based helium miner focused on Montana in the US - Completes drilling at the Inez 1 well at its Rudyard project in Montana. It reaches a total depth of 6,510 feet drilled in 19 days, with significant helium gas-shows up to 948 parts per million in drilling mud. "Helix Exploration continues to deliver with the completion of drilling at our fourth production well," says Chief Executive Officer Bo Sears. "This is our first extension well approximately two miles south of Linda 1 and within the grand Rudyard Field anticline - an expansive geologic structure confirmed by both seismic and shallow historical drilling. Inez 1 confirms the continuation of helium-bearing intervals across a broader portion of the structure, significantly enhancing our understanding of its scale and potential. Helix will now move directly on to wireline logging and flow testing of the Inez 1 well."
----------
Burford Capital Ltd - litigation finance provider with offices in London and New York - Completes its new issuance of USD500 million in senior notes on Friday. Intends to use the net proceeds from the offering to repay bonds due in 2025 at their maturity date and the remainder for general corporate purposes. "We're very pleased with the results of this latest debt offering, which added a half-billion dollars in capital, building on our momentum and strengthening our position to achieve our growth targets," says Chief Executive Officer Christopher Bogart. "The offering was substantially oversubscribed, reflecting strong demand and market confidence in Burford's performance, and enabling us to increase the size of the issuance while simultaneously decreasing its price. Ultimately, we priced a USD500 million, eight-year bond at 7.50%, which represents the most competitive pricing relative to Treasuries that Burford has ever achieved. Burford's ready access to significant capital on desirable terms sets us apart from our peers and reaffirms our position of global leadership."
----------
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Ondine BiomedFragrant Prosp.Helix ExplorationBurford Capital